Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is characterized by fat accumulation, inflammation, and scarring in the liver.
MASLD includes patients with hepatic steatosis and at least one of the following cardiometabolic risk factors:
The spectrum of MASLD ranges from simple steatosis, which is typically nonprogressive, to metabolic dysfunction-associated steatohepatitis (MASH), a progressive form that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma.
High-risk groups targeted for screening:
Symptoms of metabolic dysfunction-associated steatohepatitis (MASH) usually emerge only after MASLD has advanced. These symptoms may include pain and swelling in the upper right abdomen, indicating inflammation. However, they may not become noticeable until MASH has progressed to more severe liver damage. MASLD lays the groundwork for MASH but often presents without symptoms.
Recommended weight loss: In general, it is recommend losing at least 3% to 5% of your body weight to begin to see results in your liver.
How can I reduce my risk of developing metabolic dysfunction-associated steatotic liver disease?